Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity

A serious adverse effect of cancer therapies is cardiovascular toxicity, which significantly limits the widespread use antineoplastic agents. The promising new field cardio-oncology offers identification potent anti-cancer therapeutics that effectively inhibit cell proliferation without causing cardiotoxicity. Future introduction recently identified cardio-safe compounds into clinical practice (including ERK dimerization inhibitors or BAX allosteric inhibitors) expected to help oncologists avoid unwanted cardiological complications associated with therapeutic interventions.